GenScript Losses Widen, But Investors Focus on Newly Approved Cancer Treatment

Key takeaways:

• GenScript Biotech said it lost up to $519 million last year, with its Legend Biotech unit accounting for nearly 70% of that
• Legend Biotech’s Cilta-cel CAR-T cell therapy product was approved by the FDA on Monday, and could become a major cash cow for GenScript Biotech